179 related articles for article (PubMed ID: 28456730)
1. Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine.
Marsousi N; Desmeules JA; Rudaz S; Daali Y
J Pharm Sci; 2017 Sep; 106(9):2380-2391. PubMed ID: 28456730
[TBL] [Abstract][Full Text] [Related]
2. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.
Hartmanshenn C; Scherholz M; Androulakis IP
J Pharmacokinet Pharmacodyn; 2016 Oct; 43(5):481-504. PubMed ID: 27647273
[TBL] [Abstract][Full Text] [Related]
3. Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics.
Howard M; Barber J; Alizai N; Rostami-Hodjegan A
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1315-1330. PubMed ID: 30465453
[TBL] [Abstract][Full Text] [Related]
4. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Johnson TN; Rostami-Hodjegan A
Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
[TBL] [Abstract][Full Text] [Related]
6. The Promises of Quantitative Proteomics in Precision Medicine.
Prasad B; Vrana M; Mehrotra A; Johnson K; Bhatt DK
J Pharm Sci; 2017 Mar; 106(3):738-744. PubMed ID: 27939376
[TBL] [Abstract][Full Text] [Related]
7. Pharmacometrics in pregnancy: An unmet need.
Ke AB; Rostami-Hodjegan A; Zhao P; Unadkat JD
Annu Rev Pharmacol Toxicol; 2014; 54():53-69. PubMed ID: 24392692
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.
Tylutki Z; Mendyk A; Polak S
J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):663-677. PubMed ID: 29943290
[TBL] [Abstract][Full Text] [Related]
9. The Role of "Physiologically Based Pharmacokinetic Model (PBPK)" New Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk Assessment.
Deepika D; Kumar V
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834167
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.
Rhee SJ; Chung H; Yi S; Yu KS; Chung JY
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):973-980. PubMed ID: 28536774
[TBL] [Abstract][Full Text] [Related]
11. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic (PBPK) modeling in children.
Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
[TBL] [Abstract][Full Text] [Related]
13. Toward Greater Insights on Applications of Modeling and Simulation in Pregnancy.
Song L; Cui C; Zhou Y; Dong Z; Yu Z; Xu Y; Zhou T; Abduljalil K; Han H; Li L; Yang J; Zhao Y; Li H; Liu D
Curr Drug Metab; 2020; 21(9):722-741. PubMed ID: 32895038
[TBL] [Abstract][Full Text] [Related]
14. In Vitro-In Vivo Correlation Using In Silico Modeling of Physiological Properties, Metabolites, and Intestinal Metabolism.
Choi SM; Kang CY; Lee BJ; Park JB
Curr Drug Metab; 2017; 18(11):973-982. PubMed ID: 29086683
[TBL] [Abstract][Full Text] [Related]
15. Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation.
Franchetti Y; Nolin TD
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S36-S51. PubMed ID: 33205428
[TBL] [Abstract][Full Text] [Related]
16. Pediatric Dose Selection and Utility of PBPK in Determining Dose.
Templeton IE; Jones NS; Musib L
AAPS J; 2018 Feb; 20(2):31. PubMed ID: 29441439
[TBL] [Abstract][Full Text] [Related]
17. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
18. Model-Informed Dose Optimization in Pregnancy.
Chaphekar N; Caritis S; Venkataramanan R
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S63-S76. PubMed ID: 33205432
[TBL] [Abstract][Full Text] [Related]
19. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).
Vizirianakis IS; Mystridis GA; Avgoustakis K; Fatouros DG; Spanakis M
Oncol Rep; 2016 Apr; 35(4):1891-904. PubMed ID: 26781205
[TBL] [Abstract][Full Text] [Related]
20. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.
De Sousa Mendes M; Hirt D; Urien S; Valade E; Bouazza N; Foissac F; Blanche S; Treluyer JM; Benaboud S
Br J Clin Pharmacol; 2015 Nov; 80(5):1031-41. PubMed ID: 26011128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
